Sign in
Taking people in United StatesPhase 4

Better Options for Chronic Cancer Pain

Key facts

Who runs it
VA Office of Research and Development
Where
Ann Arbor and Indianapolis, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
294 people, planned
Started
7 Oct 2025
Expected to end
31 Dec 2029
Type of study
Interventional, 6 groups
Treatments tested
  • Multimodal pain care
  • Medication optimization
  • Buprenorphine rotation
  • Opioid tapering
Record updated
11 May 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Veterans must have had a qualifying solid tumor (bladder, breast, colorectal, head and neck, liver, lung, pancreas, prostate, or urinary tract) without evidence of active disease for at least 6 months
  • Participants must be 6 months away from their last receipt of cytotoxic, radiation, or surgical cancer treatments but can be on hormonal or biologic therapies needed to sustain remission or cancer control
  • Participants must report pain >=4 (on 0-10 NRS) on their last 3 recordings in the electronic medical record. Veterans should be on Long Term Opioid Therapy (LTOT) defined as:; a qualifying opioid analgesic dispensed within the prior 30 days; plus 150 days' supply of a qualifying opioid (fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone) in the 180 days before the most recent dispensing date with no between-fill gaps >40 days
  • There must be advance agreement from their existing opioid prescriber to resume opioid prescribing after study

Who cannot take part

  • Veterans with total daily opioid doses >= 300 Morphine Milligram Equivalents (MME) will be excluded (higher doses require tapering prior to rotation to buprenorphine, which is something the investigators do not want to examine in this study)
  • Veterans with referrals or visits to a substance abuse clinic within the prior 2 years will be excluded to avoid including individuals requiring addiction expertise that is not available one the multidisciplinary pain teams
  • The investigators will also exclude Veterans with:; current or past use of buprenorphine; active alcohol use disorder or substance use; risk factors for opioid overdose (e.g. active suicidality or history of self-directed violence); daily use of benzodiazepines; receipt of opioids from non-VA providers in the prior 3 months; or aberrant urine drug screen at baseline (cannabis is not exclusionary)
  • To ensure the relevance of our work to as many Veteran cancer survivors as possible, the investigators will not exclude subjects meeting DSM criteria for opioid use disorder if their only source of opioids is the VA

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • VA Ann Arbor Healthcare System, Ann Arbor, MIAnn Arbor, United StatesContact: Maria J Silveira, MD MA MPHTaking people
  • Richard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis, United StatesContact: David Haggstrom, MDNot yet recruiting

About the trial

What the trial wants to find out

This proposal is relevant to the 240,000 cancer survivors who continue to use opioids long after they have successfully completed treatment for cancer at the VHA, placing them at risk of opioid addiction and overdose, and other opioid-related problems. Yet, there are no programs at the VHA to help them find alternatives to opioids, nor evidence to inform the choice of interventions. This study will meet these needs by examining four interventions that are effective at reducing opioid use in patients with chronic musculoskeletal pain but have yet to be tested in cancer survivors on long term opioid therapy. The proposed work is relevant to the VHA Pain Office's mission to provide Veterans better pain management while limiting the risks of long-term opioid therapy and it aligns with VHA Research and Development's priority to examine clinical interventions for tapering opioids. Successful completion this project will keep VHA at the forefront of the battle against the opioid epidemic with a strategy that may be adapted to address the same needs in non-Veterans.

The 6 groups in the trial

  • Multimodal pain care 9 monthsTreatment being tested

    Findings from the comprehensive pain assessment will be used to inform an individualized, multimodal plan crafted by the team physician with the subject's collaboration

    Treatment: Multimodal pain care

  • Medication optimizationTreatment being tested

    Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan.

    Treatment: Multimodal pain care and Buprenorphine rotation

  • Multimodal pain care 6 months / Opioid tapering 3 monthsTreatment being tested

    Findings from the comprehensive pain assessment will be used to inform an individualized, multimodal plan crafted by the team physician with the subject's collaboration. After 6 mo, subjects will attempt to taper opioids

    Treatment: Multimodal pain care and Opioid tapering

  • Medication optimization 9 monthsTreatment being tested

    Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.

    Treatment: Medication optimization

  • Medication optimization 6 months/ Buprenorphine rotation 3 monthsTreatment being tested

    Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain. After 6mo, subjects will receive buprenorphine and attempt to taper opioids for following 3 mo.

    Treatment: Medication optimization and Buprenorphine rotation

  • Medication optimization 6 months/ Opioid tapering 3 monthsTreatment being tested

    Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain. After 6mo, subjects will attempt to taper opioids for following 3 mo.

    Treatment: Medication optimization and Opioid tapering

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Better Options for Chronic Cancer Pain: a SMART Study
Fit questions
Built from NCT06574009, who can take part
Record updated
11 May 2026